Document is current
Any future updates will be listed below
-
Authors
Soler-Espejo, Eva
Rivera-Caravaca, José Miguel https://orcid.org/0000-0003-0492-6241
Bru-Cánovas, José Daniel
Esteve-Pastor, María Asunción
Lip, Gregory Yoke Hong
Marín, Francisco
Roldán, Vanessa
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/01375)
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature
Universidad de Murcia
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 29 June 2024
First Online: 4 July 2024
Declarations
:
: Gregory Y.H. Lip: consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. José Miguel Rivera-Caravaca: Consultant for Idorsia Pharmaceuticals LTD. Francisco Marín is consultant and speaker for Boehringer-Ingelheim and BMS/Pfizer. There is nothing to disclose for other authors.
: The study protocol was approved by the Ethics Committee from the University Hospital Morales Meseguer (reference: EST: 20/16) and carried out in accordance with the ethical standards established in the 1964 Declaration of Helsinki its subsequent amendments. Informed consent was required to participation in this study.
